World Autoinjectors Market 2018-2024: Market is Estimated to Witness a CAGR of 17.1% - Key Manufacturers are Concentrating on Innovative Marketing Tactics
DUBLIN, Jan. 14, 2019 /PRNewswire/ --
The "Autoinjectors Market Forecast up to 2024" report has been added to ResearchAndMarkets.com's offering.
The global autoinjectors market is estimated to witness a CAGR of 17.1% during the forecast period 2018-2024. The autoinjectors market is analyzed based on three segments - products, applications, and regions.
The medical devices that are primarily used for the self-injection of drugs, classically life-saving drugs, are known as autoinjectors. These devices are gaining increased importance for the management of anaphylaxis, diabetes, rheumatoid arthritis, multiple sclerosis, and others. Autoinjectors are relaxed to use and proposed for self-administration by individuals either at caretakers premises or at home.
Raising prevalence of serious medical conditions such as anaphylaxis & other food allergies, advancements in the autoinjectors technology, increasing demand for home healthcare, and the rising need for self-injectors are the factors aiding the growth of the autoinjectors market.
Novel formulations of drugs and advancements in drug delivery systems along with favorable government regulations are providing an opportunity for the market growth. However, recent product recalls by the companies and the availability of substitutes for autoinjectors are hampering the market growth.
Market Analysis:
Regional Analysis: North America accounts for the largest share of the autoinjectors market, followed by Europe, Asia Pacific, and Rest of the World. More than 65% of the market is occupied by North America, with the US being the major contributor to the market growth.
Product Analysis: Based on the products, the market is segmented into disposable autoinjectors and reusable autoinjectors. Disposable autoinjectors hold dominant market share and is also the fastest growing segment in the market.
Application Analysis: Based on the application areas, the market is segmented into anaphylaxis, multiple sclerosis, rheumatoid arthritis, diabetes, and others. The market is dominated by anaphylaxis owing to a high prevalence rate globally. The fastest growing segment of the market is rheumatoid arthritis due to increased development of novel drugs for the treatment of the condition.
Key Players: The major players in the market are Mylan NV, Novartis AG, Amgen, Inc., Becton Dickinson and Company, Bayer AG, and Eli Lilly & Company Ltd. The other key players in the market include Ypsomed Holding AG, Biogen Pharmaceuticals, Pfizer Inc., Teva Pharmaceutical, Antares Pharma, Inc., Johnson and Johnson, and AbbVie, Inc.
Competitive Analysis: The key manufacturers of autoinjectors are concentrating on innovative marketing tactics to expand the reach of their products globally. Increasing awareness campaigns and price reduction of branded devices are among the strategies used by the leading companies to manage intense competition in the market.
Many companies are rebranding their autoinjectors with worthwhile reductions in the price. In December 2016, Mylan launched the generic version of EpiPen to provide autoinjector for customers at lesser prices. This approach ought to help the company in targeting a larger customer pool, thus increasing the company's customer base in recent years.
Key Topics Covered:
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition
3.2 Segmented Addressable Market
3.3 Industry Trends
3.4 Related Markets
3.4.1 Transdermal Drug Delivery
3.4.1.1 Trends of cardiovascular drugs market
3.4.2 Pulmonary Drug Delivery Systems (PDDS)
3.4.3 Insulin Pumps
4 Market Outlook
4.1 Cost comparison of EpiPen and its Alternatives
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 Market Characteristics
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of Anaphylaxis
5.1.1.2 Rising incidence of chronic disease
5.1.1.3 Increased Development Biologics / Biosimilars
5.1.1.4 Growing demand for home care
5.1.2 Opportunities
5.1.2.1 Increase in healthcare spending
5.1.2.2 Opportunities in emerging market
5.1.2.3 Favorable government policies
5.1.3 Restraints
5.1.3.1 Competition among major vendors
5.1.3.2 Increased product recall
5.1.3.3 High product pricing
5.2 DRO - Impact Analysis
5.3 Key Stakeholders
6 Application: Market Size and Analysis
6.1 Overview
6.2 Anaphylaxis
6.3 Multiple Sclerosis
6.4 Rheumatoid Arthritis
6.5 Diabetes
6.6 Others
7 Product Type: Market Size and Analysis
7.1 Overview
7.2 Disposable autoinjector
7.3 Reusable autoinjectors
8 Regions: Market Size and Analysis
8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia Pacific
8.5 Rest of the World
9 Competitive Landscape
10 Vendors Profiles
- AbbVie Inc
- Amgen Inc.
- Antares Pharma Inc.
- Bayer AG
- Becton Dickinson and Company
- Biogen Pharmaceuticals
- Eli Lilly & Company Ltd
- Johnson and Johnson
- Mylan NV
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical
- Ypsomed Holding AG
For more information about this report visit https://www.researchandmarkets.com/research/jbt4lb/woruld?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article